Myocet liposomal (previously Myocet)



This medicine is authorised for use in the European Union.


Myocet liposomal is a cancer medicine for use with cyclophosphamide (another cancer medicine) to treat women with metastatic breast cancer. ‘Metastatic’ means that the cancer has spread to other parts of the body.

Myocet liposomal contains the active substance doxorubicin.

This EPAR was last updated on 24/03/2023

Authorisation details

Product details
Myocet liposomal (previously Myocet)
Agency product number
Active substance
doxorubicin hydrochloride
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Breast Neoplasms
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Teva B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Swensweg 5
2031GA Haarlem
The Netherlands

Product information

15/12/2022 Myocet liposomal (previously Myocet) - EMEA/H/C/000297 - II/0070

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.

Assessment history

How useful was this page?

Add your rating